文献速递乳房整形与再造

乳房再造临床试验中的报告偏倚:哪些临床试验何时得以发表

Reporting bias in breast reconstruction clinical trials: Which and when clinical trials get published.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2024-02-09

本研究检索ClinicalTrials.gov自建库至2020年8月所有已完成的乳房再造临床试验,共识别156项试验,其中53项已发表。中位发表时间22个月(IQR 13-35个月)。行业资助研究发表时间更长(HR=2.4,p=0.023)且发表于较低影响力期刊(OR=3.7,p=0.048)。随机对照试验发表速度快于非随机研究(aHR=3.2,p=0.030)。

要点

  • 156项已完成乳房再造临床试验中仅53项发表。
  • 行业资助研究发表时间更长(HR=2.4,p=0.023)。
  • 行业资助研究更易发表于较低影响力期刊(OR=3.7,p=0.048)。

核心结论

  • 未发现行业资助试验更可能报告阳性主要结局的证据。
  • 行业资助试验与更长的发表时间及发表于较低影响力期刊相关。

研究设计与样本

  • 检索ClinicalTrials.gov自建库至2020年8月所有已完成的乳房再造临床试验。
  • 共识别156项临床试验,其中53项已发表。
  • 采用时间-事件分析比较发表时间,采用logistic回归评估与发表相关的试验特征。

主要发现

  • 156项试验中53项发表,中位发表时间22个月(IQR 13-35个月)。
  • 行业资助研究发表时间更长(HR=2.4,p=0.023)。
  • 行业资助研究更易发表于较低影响力期刊(OR=3.7,p=0.048)。
  • 随机临床试验发表速度快于非随机研究(aHR=3.2,p=0.030)。
  • 统计学显著性和效应量与发表时间无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reporting bias refers to the phenomenon in which the reporting of research findings is influenced by the nature of the results. Without the totality of evidence, clinical practice may be misguided. The objective of this work was to examine the extent of reporting bias in clinical trials of breast reconstruction surgery. METHODS: We searched and extracted data from all completed breast reconstruction clinical trials published in ClinicalTrials.gov from database inception to August 2020. Investigators sought to identify published full manuscripts of the registered trials. The primary outcome was classified as positive or nonpositive and trials were classified as industry or nonindustry funded. Time to publication in a peer-reviewed journal was computed and compared using time-to-event analysis. Trial characteristics associated with publication were evaluated using logistic regression. RESULTS: A total of 156 clinical trials were identified, of which, 53 trials were published. The median time to publication was 22 months (IQR, 13-35 months). Industry-funded studies were associated with a longer time to publication (HR = 2.4, p = 0.023) and publication in lower-impact journals (OR = 3.7, p = 0.048). Randomized clinical trials were associated with faster times to publication than nonrandomized studies (aHR = 3.2, p = 0.030). Statistical significance and the effect size were not associated with time to publication. CONCLUSIONS: We found no evidence that industry-funded trials were more likely to report a positive primary outcome. However, industry-funded trials were associated with a longer time to publication and publication in lower-impact journals.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Olaiya OR, Abraha B, Ogbeide OJ, et al. Reporting bias in breast reconstruction clinical trials: Which and when clinical trials get published. J Plast Reconstr Aesthet Surg. 2024. PMID: 38461624. doi:10.1016/j.bjps.2024.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。